within Pharmacolibrary.Drugs.ATC.A;

model A10BH51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.87,
    Cl             = 0.0032,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.198,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BH51</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sitagliptin and simvastatin is a fixed-dose combination drug approved for use in the management of type 2 diabetes mellitus and dyslipidemia. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control, while simvastatin is a HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk. This combination allows for convenient co-administration to patients requiring both glycemic and cholesterol management.</p><h4>Pharmacokinetics</h4><p>No published population pharmacokinetic parameters are available specifically for the fixed-dose combination of sitagliptin and simvastatin (ATC A10BH51). Below are estimated parameters based on available data for the individual monotherapies in healthy adults receiving typical oral doses.</p><h4>References</h4><ol><li><p>Steinberg, H, et al., &amp; Engel, SS (2013). Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. <i>Vascular health and risk management</i> 9 273–282. DOI:<a href=\"https://doi.org/10.2147/VHRM.S44330\">10.2147/VHRM.S44330</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23761972/\">https://pubmed.ncbi.nlm.nih.gov/23761972</a></p></li><li><p>Burugula, L, et al., &amp; Kandhagatla, R (2013). Simultaneous determination of sitagliptin and simvastatin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. <i>Biomedical chromatography : BMC</i> 27(1) 80–87. DOI:<a href=\"https://doi.org/10.1002/bmc.2751\">10.1002/bmc.2751</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22544712/\">https://pubmed.ncbi.nlm.nih.gov/22544712</a></p></li><li><p>Pham, DQ, et al., &amp; Plakogiannis, R (2008). Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 65(6) 521–531. DOI:<a href=\"https://doi.org/10.2146/ajhp070248\">10.2146/ajhp070248</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18319497/\">https://pubmed.ncbi.nlm.nih.gov/18319497</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BH51;
